Addition of interferon-alpha to the p53-SLP (R) vaccine results in increased production of interferon-gamma in vaccinated colorectal cancer patients: A phase I/II clinical trial

Author(s):
Zeestraten, E.C.M.; Speetjens, F.M.; Welters, M.J.P.; Saadatmand, S.; Stynenbosch, L.F.M.; Jongen, R.; Kapiteijn, E.; Gelderblom, H.; Nijman, H.W.; Valentijn, A.R.P.M.; Oostendorp, J.; Fathers, L.M.; Drijfhout, J.W. (0000-0003-4808-5296); Velde, C.J.H. van de (0000-0003-0104-1800); Kuppen, P.J.K. (0000-0002-0294-3251); Burg, S.H. van der (0000-0002-6556-0354); Melief, C.J.M.
Published
2013
Publication type
Article / Letter to editor
p53immunotherapycoloncolorectalcancervaccinesynthetic long peptidesimmune monitoringtherapeuticIFN-a
Date issued
2013-04-01
Language
English
Is part of
hdl
1887/97264
doi
10.1002/ijc.27819